Joseph Chao

13PUBLICATIONS
75CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersSolid tumoursEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.

Filippo Pietrantonio, Lisa Salvatore, Taito Esaki

|Feb 05, 2025
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers.

Andrew H Ko, Joseph Chao, Marcus S Noel

|May 09, 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.

Susanna Hegewisch-Becker, Guillermo Mendez, Joseph Chao

|Feb 05, 2024
Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells.

Gregory P Botta, Joseph Chao, Hong Ma

|Mar 27, 2023
Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes.

Raisa Epistola, Rubens Sperandio, Zev Wainberg

|Dec 08, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers.

Brandon M Huffman, Vasily N Aushev, Griffin L Budde

Pageof 3

Frequent Collaborators

5 joint publications

Samuel J Klempner

3 joint publications

Steven B Maron

3 joint publications

Daniel V T Catenacci

3 joint publications

Filippo Pietrantonio